Based on these findings, in which ACC-1 is identified as a potential treatment target, the present research explores this enzyme as a promising candidate for early diagnosis of NAFLD, both in vitro and in vivo. The gene discussed is ACACA; the disease is metabolic dysfunction-associated steatotic liver disease.